Nephrotoxicity of the BRAF Inhibitors Vemurafenib and Dabrafenib-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Nephrotoxicity of the BRAF Inhibitors Vemurafenib and Dabrafenib

Published:2015-11-01 Issue:8 Volume:1 Page:1133
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Jhaveri Kenar D.¹,Sakhiya Vipulbhai¹,Fishbane Steven¹

Affiliation:

1. Division of Nephrology, Hofstra North Shore LIJ School of Medicine, North Shore University Medical Center, Long Island Jewish Medical Center, Great Neck, New York

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Cited by 80 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cancer therapy in patients with reduced kidney function;Nephrology Dialysis Transplantation;2024-06-24

2. Pharmacotherapy considerations in patients who develop acute kidney injury during anti-cancer therapy;Expert Opinion on Pharmacotherapy;2024-03-23

3. Onco-Hypertension in Patients with Kidney Disease;American Journal of Nephrology;2024-03-18

4. Acute and chronic kidney function decline in patients receiving BRAF/MEK inhibitors for melanoma;Nephrology Dialysis Transplantation;2024-02-22

5. Dabrafenib and steroids for the treatment of Erdheim-Chester disease with extensive CNS involvement: a case report;Personalized Medicine;2024-01-26

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP